Q32 BIO INC (QTTB)

Noteworthy Wednesday Option Activity: BURL, LOVE, QTTB

Wednesday's session: top gainers and losers

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Which stocks are experiencing notable movement on Wednesday?

Which stocks are experiencing notable movement on Wednesday?

The market is filled with gapping stocks in Wednesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Gap analysis on 2024-12-11: gap up and gap down stocks in today's session.

Q32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia Treatment

The company scrapped its treatment for eczema, though continues working in alopecia.

Top movers in Wednesday's pre-market session

Top movers in Wednesday's pre-market session

Which stocks are moving after the closing bell on Tuesday?

As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

-- SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score...

Q32 Bio Breaks Below 200-Day Moving Average - Notable for QTTB

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

-- Bempikibart Phase 2 topline results in atopic dermatitis (AD) and alopecia areata (AA) remain on-track for Q4'24, with topline data from both trials...

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

/PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

/PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...

Q32 Bio to Participate in Upcoming September Investor Conferences

/PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...

QTTB Stock Earnings: Q32 Bio Misses EPS for Q2 2024

QTTB stock results show that Q32 Bio missed analyst estimates for earnings per share the second quarter of 2024.

QTTB Stock Earnings: Q32 Bio Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Q32 Bio (NASDAQ:QTTB) just reported results for the second quarter of 2024.Q32 ...

Q32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

-- Completed enrollment in bempikibart atopic dermatitis (AD) Phase 2 clinical trial and increased trial size to 121 patients based on Part B patient demand --...

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

/PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...

Q32 Bio Joins Russell 3000® Index

/PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...

QTTB Stock Earnings: Q32 Bio Misses EPS for Q1 2024

QTTB stock results show that Q32 Bio missed analyst estimates for earnings per share the first quarter of 2024.

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

-- Completed enrollment in bempikibart alopecia areata (AA) Phase 2 clinical trial, with topline results expected in Q4'24; enrollment in bempikibart atopic...

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

/PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune...

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

-- Q32 Bio to focus on advancement of bempikibart (ADX-914) in ongoing atopic dermatitis (AD) and alopecia areata (AA) Phase 2 clinical trials and commencement...